China’s Asieris Bets On Bladder Cancer With Rediscovered Asset From Johns Hopkins
Emerging Company Profile: Aiming to change the current practice of surgically removing the bladder, China Asieris hopes to use an older drug to treat early-onset bladder cancer. This is the fourth and last in a series of China-based Emerging Company Profiles.
You may also be interested in...
Established just a year ago, China's Lepu Biotech has raised a mighty $131m to develop immuno-oncology antibodies, while Shanghai-based Asieris has obtained worldwide rights to develop and commercialize Photocure's Cevira for cervical dysplasia.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.
In a shocking and revealing account, a primary investigator of the front-runner antiviral drug for the coronavirus in China expresses concerns over finding enough patients for the study Wuhan, the outbreak's epicenter.